FRESENIUS MEDICAL CARE AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.18 EUR | +0.31% |
|
+0.46% | +3.21% |
| May. 28 | FMC briefly burdened by research success in the fight against diabetes | DP |
| May. 28 | FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Berenberg reaffirms its Buy rating | ZD |
| Sales 2024 * | 19.56B 21.21B | Sales 2025 * | 20.3B 22.01B | Capitalization | 11.5B 12.47B |
|---|---|---|---|---|---|
| Net income 2024 * | 665M 721M | Net income 2025 * | 964M 1.05B | EV / Sales 2024 * | 1.1 x |
| Net Debt 2024 * | 9.93B 10.77B | Net Debt 2025 * | 8.98B 9.74B | EV / Sales 2025 * | 1.01 x |
| P/E ratio 2024 * |
17.2
x | P/E ratio 2025 * |
12
x | Employees | 117,128 |
| Yield 2024 * |
2.75% | Yield 2025 * |
3.33% | Free-Float | 67.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fresenius Medical Care AG
More recommendations
More press releases
More news
| 1 day | +0.31% | ||
| 1 week | +0.46% | ||
| 1 month | -1.06% | ||
| 3 months | +9.96% | ||
| 6 months | +3.11% | ||
| Current year | +3.21% |
1 week
37.91
39.48
1 month
36.5742.12
Current year
33.8842.12
1 year
30.1649.62
3 years
25.9571.14
5 years
25.9581.10
10 years
25.9593.82
| Managers | Title | Age | Since |
|---|---|---|---|
Helen Giza
CEO | Chief Executive Officer | 56 | 19-10-31 |
Martin Fischer
DFI | Director of Finance/CFO | 47 | 23-09-30 |
Franklin Maddux
CTO | Chief Tech/Sci/R&D Officer | 65 | 08-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 16-05-11 |
Shervin Korangy
BRD | Director/Board Member | 50 | 23-07-13 |
Marcus Kuhnert
BRD | Director/Board Member | 56 | 23-07-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.48% | 202 M€ | -.--% | ||
| 1.12% | 2 M€ | +13.56% | - | |
| 0.80% | 79 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 39.18 | +0.31% | 828,830 |
| 24-05-30 | 39.06 | +1.85% | 351,321 |
| 24-05-29 | 38.35 | -2.47% | 302,494 |
| 24-05-28 | 39.32 | +1.42% | 570,731 |
| 24-05-27 | 38.77 | -0.59% | 249,386 |
Delayed Quote Xetra, May 31, 2024 at 11:35 am EDT
More quotes
Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Calendar
2024-07-29
- Q2 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
39.18
EUR
Average target price
39.92
EUR
Spread / Average Target
+1.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.21% | 12.47B | |
| +25.52% | 88.99B | |
| -24.52% | 74.82B | |
| -5.56% | 25.03B | |
| +4.31% | 17.88B | |
| -14.25% | 16.43B | |
| +2.97% | 15.77B | |
| +79.20% | 13.21B | |
| +70.11% | 13.09B | |
| +40.44% | 12.9B |
- Stock Market
- Equities
- FME Stock
